KR20170088894A - Parp 억제제의 결정질 형태 - Google Patents

Parp 억제제의 결정질 형태 Download PDF

Info

Publication number
KR20170088894A
KR20170088894A KR1020177016523A KR20177016523A KR20170088894A KR 20170088894 A KR20170088894 A KR 20170088894A KR 1020177016523 A KR1020177016523 A KR 1020177016523A KR 20177016523 A KR20177016523 A KR 20177016523A KR 20170088894 A KR20170088894 A KR 20170088894A
Authority
KR
South Korea
Prior art keywords
compound
crystalline form
further characterized
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177016523A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 제이. 비얼마이어
랄프 씨. 할티원저
마틴 제이. 제이콥스
Original Assignee
세파론, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세파론, 인코포레이티드 filed Critical 세파론, 인코포레이티드
Publication of KR20170088894A publication Critical patent/KR20170088894A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020177016523A 2014-11-26 2015-11-25 Parp 억제제의 결정질 형태 Withdrawn KR20170088894A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084652P 2014-11-26 2014-11-26
US62/084,652 2014-11-26
PCT/US2015/062572 WO2016086080A1 (en) 2014-11-26 2015-11-25 Crystalline forms of parp inhibitors

Publications (1)

Publication Number Publication Date
KR20170088894A true KR20170088894A (ko) 2017-08-02

Family

ID=54849709

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177016523A Withdrawn KR20170088894A (ko) 2014-11-26 2015-11-25 Parp 억제제의 결정질 형태

Country Status (13)

Country Link
US (1) US10150772B2 (cg-RX-API-DMAC7.html)
EP (1) EP3224259A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017535564A (cg-RX-API-DMAC7.html)
KR (1) KR20170088894A (cg-RX-API-DMAC7.html)
CN (1) CN107207511A (cg-RX-API-DMAC7.html)
AU (1) AU2015353549A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017010588A2 (cg-RX-API-DMAC7.html)
CA (1) CA2967828A1 (cg-RX-API-DMAC7.html)
HK (1) HK1244006A1 (cg-RX-API-DMAC7.html)
IL (1) IL252162A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017006679A (cg-RX-API-DMAC7.html)
RU (1) RU2017120655A (cg-RX-API-DMAC7.html)
WO (1) WO2016086080A1 (cg-RX-API-DMAC7.html)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
US20060276497A1 (en) 2000-05-09 2006-12-07 Cephalon, Inc. Novel multicyclic compounds and the use thereof
WO2008063644A1 (en) * 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Also Published As

Publication number Publication date
JP2017535564A (ja) 2017-11-30
CN107207511A (zh) 2017-09-26
BR112017010588A2 (pt) 2018-05-15
US10150772B2 (en) 2018-12-11
MX2017006679A (es) 2018-07-06
WO2016086080A1 (en) 2016-06-02
EP3224259A1 (en) 2017-10-04
CA2967828A1 (en) 2016-06-02
IL252162A0 (en) 2017-07-31
RU2017120655A3 (cg-RX-API-DMAC7.html) 2018-12-14
US20170267683A1 (en) 2017-09-21
AU2015353549A1 (en) 2017-06-01
RU2017120655A (ru) 2018-12-14
HK1244006A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
KR102845326B1 (ko) Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태
TW201109334A (en) PLK inhibitor salts
US10927142B2 (en) Salts and polymorphs of SCY-078
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
CN117736176A (zh) 雄激素受体拮抗剂的可药用盐及其多晶型物、制备方法和用途
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
WO2020025449A1 (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
US10150772B2 (en) Crystalline forms of PARP inhibitors
EP2922838B1 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
EP4169914A1 (en) Salt of compound and pharmaceutical composition containing salt
CN102725294B (zh) (s)-1-(4-(5-环丙基-1h-吡唑-3-基氨基)吡咯并[1,2-f][1,2,4]三嗪-2-基)-n-(6-氟吡啶-3-基)-2-甲基吡咯烷-2-甲酰胺的晶型
KR20260066052A (ko) 베주클라스티닙의 결정형, 이의 제조방법 및 이의 용도
HK40079381A (en) Novel salts and polymorphs of scy-078
CN107868059B (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt
AU2021231396A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine
TW202540110A (zh) 化合物鹽的晶型及其製備方法和用途
CN119504757A (zh) 一种jak激酶抑制剂的盐的晶型
HK1247196B (en) Novel salts and polymorphs of scy-078

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170615

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination